Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.

Main inclusion criteria: * Age between 18 and 60 years-old * BMI between 18 and 30 kg/m2 * Diagnostic of idiopathic hypersomnia (ICSD-3 criteria) made in the last 5 years, based on Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, showing either: a mean sleep latency (MSL) of ≤8 minutes and \< 2 SOREMPs and/or a 24-h long term polysomnography recording showing total sleep time \>11h/24 hours. * Apnea-hypopnea index (AHI) \<15/hour, Apnea index \<10/hour, micro-arousals index \<15/hour, Periodic limb movement (PLM) index associated with micro-arousals \<15/hour on the PSG and MSLT performed within the past 5 years. * Absence of sleep deprivation, assessed by actigraphy or sleep logs for the 7 days preceding study inclusion * ESS score ≥11 points * Written informed consent * National health insurance coverage * Understand, read and speaks French well * The participant agrees to follow the contraceptive requirements detailed in the protocol. Main non-inclusion criteria * Non-stabilized hypertension * To be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within the past year before screening, or has positive answers on items number 4 or 5 on the Colombia-Suicide Severity Rating Scale (based on the 6 months before randomization). * Other psychiatric conditions in the past 6 months * Presence of other central nervous system diseases: neurodegenerative diseases, seizure disorders, or history of head …